Opthea Announces Decision to Discontinue Wet AMD Trials

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52

Opthea and DFA Investors agreed to terminate both COAST and ShORe trials

Read more at globenewswire.com